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information to determine tumour aggressiveness. Of the total 17,045 male participants, this left 14,054 eligible. The case-cohort study included all men diagnosed with prostate cancer between baseline and 30 June 2002 and a random sample (subcohort) of all eligible men. Cases were identified from notifications of first diagnoses of prostate cancer to the Victorian Cancer Registry or the Australian Cancer Database. Aggressive tumours were defined as having a Gleason score >7, poor differentiation, stage 4 or fatal disease.
In an average of 8.9 person-years of follow-up to 30 June 2002, 487 eligible men were diagnosed with prostate cancer, 37 left Australia and 752 died from any cause. The subcohort included a random sample of 1784 men, 59 of whom were also cases. %PPL fatty acid measurements were available for 96% of members of the subcohort and 95% of cases.
There were no appreciable differences in demographics, lifestyle factors or family history of cancer between men who had their fatty acids measured and those who did not (all P>0.06). Thus, the analyses included 1717 men in the subcohort and 464 men with prostate cancer (56 of whom were in the subcohort), including 127 with aggressive tumours.
Samples for participants in the sub-cohort were selected in random order and aliquots of 200 µL in batches of 80 samples each (72 study samples and 8 control samples) were prepared. Fatty acid levels were measured in the laboratory of one of the authors (RAG), blind to case status. The %PPL fatty acid assay has been described in detail elsewhere 14 . Briefly, samples were retrieved from liquid nitrogen storage and aliquotted on ice under red light conditions before being refrozen and transported to the laboratory. Total lipids were extracted from plasma and separated by thin-layer chromatography into PPLs, triacylglycerol and cholesterol esters on silica gel plates (Silica gel 60H Merck Darmstadt Germany). PPL fatty acid methyl esters were separated and quantified with a Hewlett-Packard 5880 gas-liquid chromatograph using a capillary column equipped with flame ionization detection and Hewlett-Packard Chem-Station data system. The between batch coefficients of variation were between 1% and 12%.
We measured the following %PPL at baseline: total SFA; myristic acid (14:0); palmitic acid (16:0); stearic acid (18:0); total MUFA; palmitoleic acid (16:1n-7); oleic acid (18:1n-9); total PUFA; n-3 PUFA; α-linolenic acid (ALA, 18:3n-3); 5 Dietary intakes were estimated using a self-administered 121-item FFQ specifically developed for the MCCS and administered at baseline attendance 15 . Dietary energy intake (excluding alcohol) was calculated using sex-specific portion sizes and Australian food composition data. Dietary intakes of fatty acids were calculated using Australian fatty acid composition data 16 . To facilitate comparison of our results for %PPL and dietary fatty acids we used the casecohort sample to investigate associations with dietary fatty acids.
Assessment of other risk factors
A structured interview schedule was used to collect information on potential risk factors: age, country of birth, alcohol consumption, leisure time physical activity, smoking status, educational attainment and family history of cancer.
Statistical Analysis
Follow-up began at baseline attendance and continued until date of diagnosis of prostate cancer or unknown primary cancer, an unconfirmed diagnosis of prostate cancer, death, last known to be in Australia or 30 June 2002, whichever came first. Cox regression models were fitted, with age as the time axis, to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), separately for each %PPL and dietary fatty acid. To allow for the case-cohort design, we used Prentice weights 17 with robust standard errors. To test for heterogeneity in HRs by tumour aggressiveness, we fitted Cox regression models for competing risk using a data duplication method.
All models included country of birth (Southern Europe; Northern Europe, Australia or New Zealand); educational attainment; alcohol consumption (abstainers, former drinkers, 1-39 grams/day, 40-59 grams/day, ≥60 grams/day); physical activity (an ordinal scale based on frequency and intensity of physical activity, then grouped based on approximate quartiles); daily non-alcohol energy intake and family history of cancer. Models were stratified by smoking status (never, former, current) as tests based on Schoenfeld residuals showed that the hazards were not proportional for this variable. Additional analyses involved fitting and testing two-way interaction terms between tumour aggressiveness and each confounder in the competing risk model: no interaction was statistically significant.
Intakes of energy and each dietary fatty acid were log transformed and then the dietary fatty acids were adjusted for energy intake using the residuals method 18 . Quintile cut points (Q) for each fatty acid were obtained from the subcohort, the lowest quintile (Q1) being the referent category. To estimate linear trends on a log hazard scale, each 6 fatty acid was fitted as a pseudocontinuous covariate (using the median Q values). To investigate departures from linearity in the relationship between fatty acid intake and overall prostate cancer we also included a quadratic pseudocontinuous term for each fatty acid in these models, and assessed the significance of this term using the Wald test.
Differences in selected baseline characteristics and %PPL and dietary fatty acids were assessed using chi-square tests for categorical variables and Wilcoxon rank-sum tests for continuous variables.
We also investigated whether further adjustment of our models for intakes (from food sources only) of lycopene (µg/d), calcium (mg/d), and vitamin E (mg/d) affected the estimates. We analysed the specific trans fatty acids separately but the estimates were similar to the total trans fatty acids so we have just presented these. Selected analyses were repeated after excluding the first 2 years of follow-up and excluding men who consumed fish-oil or cod-liver oil supplements (since we could not measure these accurately because our FFQ did not allow for a quantative assessment of these).
Statistical analyses were performed using Stata/SE 11.2 (Stata Corporation, College Station, TX). P < 0.05 (two-sided) was considered statistically significant.
Results
Baseline characteristics are shown in Table 1 . Cases were older, less likely to be born in Southern Europe, had lower physical activity levels, and were more likely to be current smokers and to have had a family history of cancer (all P≤0.01). Median %PPL fatty acid and daily energy-adjusted fatty acid intakes are shown in Table 2 . Cases had significantly higher %PPL SFA, trans fatty acids and dietary n-6:n-3 PUFA, and significantly lower %PPL MUFA, oleic acid, ALA and dietary EPA and trans fatty acids (all P≤0.05).
Moderate Spearman correlations were observed between energy-adjusted dietary intakes and %PPL levels for total PUFA (ρ=0.28), n-3 PUFA (ρ=0.21), DHA (ρ=0.39), n-6 PUFA (ρ=0.34), linoleic acid (ρ=0.30) and n-6:n-3 PUFA (ρ=0.39), whereas only weak correlations were observed for all other fatty acids (all ρ<0.20).
7 Table 3 shows HRs in relation to %PPL fatty acids. We observed a positive association with total SFA (HR=1.51 [1.06, 2.16], (Q5 vs. Q1); P-trend=0.003), primarily due to palmitic acid for which HRs (Q2 to Q5) were elevated, although the test for linear trend was not significant. HRs less than unity were observed for myristic acid, but none was statistically significant. There was weak evidence of an inverse association with total MUFA (P-trend=0.07). A similar pattern was observed for oleic acid; where the HR for Q5 vs. Q1 was 0.62 [0.43, 0.91], P-trend=0.04. The inclusion of a quadratic fatty acid term indicated a departure from linearity (P-quadratic trend=0.001) for %PPL palmitic acid, with a peak at Q3 (HR=2.16 [1.46, 3.20] ), but there was no evidence of a departure from linearity in the relationships for any other %PPL fatty acid (all P>0.1). Table 4 shows HRs in relation to dietary intake of fatty acids. Although there were no statistically significant linear associations, HRs were all above unity for total PUFA and n-6 PUFA, largely attributable to linoleic acid intake.
Elevated HRs (Q5 to Q2 vs. Q1) were observed for linoleic acid, but these were statistically significant only for Q2 and Q3. For n-6:n-3 PUFA, we observed an elevated HR for Q4 vs. Q1 but no other. The inclusion of a quadratic term suggested an inverted U-shaped relationship between total dietary PUFA, n-6 PUFA and linoleic acid and risk (P=0.03, P=0.01 and P=0.01 respectively), but there was no evidence of departure from linearity for any other dietary fatty acid association (all P>0.1).
There were no associations between other %PPL or dietary fatty acid estimates and prostate cancer incidence and no observed association varied significantly by tumour aggressiveness (test for homogeneity, all P>0.09).
Further adjustment of the models for intakes of calcium, lycopene and vitamin E did not materially change the HR estimates, neither did the exclusion of the first two years of follow-up or those who consumed fish oil or cod-liver oil supplements.
Discussion
We report a positive linear association between %PPL SFA and prostate cancer risk, a non-linear relationship (with a peak at Q3) for %PPL palmitic acid and weak evidence of an inverse monotonic association for %PPL MUFA, primarily due to oleic acid. Associations we observed for dietary fatty acid intakes were not consistent with those for %PPL estimates. No association was observed to vary significantly by tumour aggressiveness.
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The case-cohort design is an efficient method for analysing time to failure in a large cohort where the outcome is rare, requiring exposure and covariate information on all failures and only a small subset of censored observations. Sampling in the case-cohort design is done a priori irrespective of case-status or time 17 . Other strengths of our study include virtually complete follow-up as the identification of incident prostate cancers was confirmed by record-linkage to cancer databases which have full geographic coverage. Our study limitations are common to others that use FFQs and biomarkers to estimate fatty acid intakes and composition. Intakes estimated from FFQs have considerable error 19 that contributes to weak and inconsistent findings as reported in a recent meta-analysis of dietary fat and prostate cancer 1 .
We measured %PPL fatty acids, which reflect short-term rather than long-term intakes 20 . Further, correlations between fatty acids make it difficult to estimate associations that are specific to a single type. For subgroups, particularly aggressive tumours, small numbers led to low precision. Given the number of comparisons performed, some associations might be due to chance alone.
Due to difficulties with estimating dietary fat intakes, biomarkers are often used. However, SFAs can be synthesized endogenously from acetyl CoA and dietary saturated fatty acids can also be endogenously altered through elongation and desaturation to produce oleic acid 21 thus PPL levels do not necessarily agree with intake estimates. Weaker correlations between %PPL and dietary fatty acids for MUFA and some SFAs may also be attributed to the relatively small range of habitual intakes of these fatty acids and large day-to-day intra-individual variation. PUFAs cannot generally be produced endogenously, thus diet and supplements are the major source, which is reflected in the stronger correlations for these fatty acids. Fatty acid concentrations can also be affected by total amount of fat consumed, genetic, lifestyle and metabolic factors, which may affect de novo fatty acid synthesis and fatty acid metabolism 21 . In this and other studies, fatty acids concentrations are usually presented as a percentage of the total, reflecting relative concentrations. Thus, changes in the intake of one fatty acid might affect the relative concentration of others, particularly for those representing lower proportions. Given these limitations, it is not surprising that the associations with prostate cancer we observed were not consistent between dietary intakes and biomarkers.
A meta-analysis of 14 studies reported a weak positive association between dietary SFA and prostate cancer (but this association was not evident in studies that adjusted for energy intake) and stronger positive associations with advanced 9 prostate cancer (based on 5 studies) but with substantial heterogeneity across studies 1 . A recent review concluded that the data were too limited to support an association between SFA intake and prostate cancer 2 . Our null finding for dietary SFA is consistent with several others [22] [23] [24] [25] [26] [27] [28] . Men consuming high SFA diets have been shown to have an increased risk of biochemical failure following prostatectomy, suggesting that SFAs might promote prostate cancer progression 29 . A recent report on SFA and cardiovascular disease (CVD) noted that associations varied depending on the source of the SFA, with those from dairy having an inverse association while those from meat showed a positive association 30 . Although we do not have data to test whether the same holds for prostate cancer, we did not find any associations between dairy 31 or meat intake and prostate cancer in our study. Fewer studies have investigated associations with biomarkers of total SFA and have not reported any association with prostate cancer 32, 33 , in contrast to the positive association we observed.
The increased prostate cancer risk we observed with higher levels of %PPL palmitic acid is consistent with other studies of blood levels 32, 34 and intakes 25 . Other studies have generally reported no overall associations 33, 35, 36 but some have found positive associations for specific subgroups 33, 36 .
Palm oil, butter, milk, cheese and meat are the main sources of palmitic acid, which can be synthesised from other fatty acids and is the major fatty acid produced by de novo lipogenesis from acetyl CoA and malonyl CoA by the enzyme fatty acid synthase. There is some evidence that de novo fatty acids are required for prostate cancer cell proliferation and survival 37 but it is still unknown whether prostate cancer cells differentially utilise de novo and dietary lipids 37 .
The increased risks we observed for palmitic acid might reflect higher fatty acid synthase activity.
Consistent with others, we observed no association with %PPL myristic 23, 34, 35 or stearic acid 23, 32, 33, 36 while other studies have reported positive associations with circulating myristic acid 32, 36 , inverse associations with circulating stearic acid 34, 35 and positive associations with myristic acid intake 25 .
Consistent with our null finding for total dietary MUFA intake, a meta-analysis of 9 studies as well as most subsequent studies found no association with either intake 1, 22, 24, 26, 28, 38 or blood levels 32, 33 of total MUFA. Oleic acid is the main 10 MUFA in both the diet and circulation. Studies of circulating oleic acid concentrations have generally shown no association with prostate cancer [32] [33] [34] [35] [36] , in contrast to the inverse association observed by us and one other study 23 . This could relate to different sources of oleic acid in the circulation. Olive oil is a particularly rich source of oleic acid but also contains other molecules which may contribute to health benefits 39 . In Australia, red meat (an important source of MUFA) is the main source of oleic acid 40 , but this does not provide antioxidants. Several molecular mechanisms have been proposed to underlie a protective effect of oleic acid, including hormonal status, cell membrane structure and function, signal transduction pathways, gene expression and the immune system 41 . Our finding of no association between dietary oleic acid and prostate cancer is consistent with a meta-analysis including 3 case-control studies, which reported no association for olive oil or MUFA derived from this 39 . The null association we observed for both dietary intake and %PPL of palmitoleic acid is consistent with others 33, 34, 36 .
Consistent with our null finding, two meta-analyses of prospective epidemiological studies report no association with αlinolenic acid (biomarker and intakes combined) and prostate cancer risk 4, 42 . In contrast, another meta-analysis of prospective studies reported slightly reduced risks of prostate cancer with dietary intake of α-linolenic acid 43 whereas a systematic review suggested that higher intakes might increase risk 3 
. The European Prospective Investigation into
Cancer and Nutrition study, not included in these reviews, also reported a positive association for %PPL α-linolenic acid with high-grade prostate cancer only 34 and a recent case-control study reported an increased risk of total prostate cancer with high dietary intake but no association with blood levels 23 . Inconsistencies between biomarkers and dietary intakes for α-linolenic acid likely reflect that the levels in plasma phospholipids are very low and the correlations between diet and PPL% are low relative to other PUFA, as we showed previously for the MCCS 14 .
Although, we did not observe any clear associations between %PPL or dietary EPA or DHA and prostate cancer, all HRs were below unity for EPA and DHA intakes. Meta-analyses of epidemiological studies 4, 7 and recent studies of circulating long chain n-3 fatty acids 33, 34, 44, 45 , report no clear associations with EPA or DHA; there is also no strong evidence for a protective effect of fish consumption 6, 7 , the main dietary source of these. Evidence from experimental studies suggests that n-3 PUFA, especially long-chain n-3 PUFA such as EPA and DHA, are negatively associated with prostate cancer 3, 46 whereas n-6 PUFA stimulates cancer progression 11 and several mechanisms have been proposed 8, 12 .
Studies of n-6 PUFAs have mainly focused on linoleic acid. We observed a threshold effect for dietary linoleic acid, with the highest HRs for the 2 nd and 3 rd quintiles relative to the lowest, but this finding was not supported by our results for %PPL, despite the moderate correlation between dietary and %PPL estimates and the fact that linoleic acid can only be acquired from diet. Others have generally failed to find clear evidence of an association with linoleic acid 3, 9, 33, 34, 44 but an inverse association was reported by the Physicians Health Study 45 . On the other hand, our findings for dietary linoleic acid are consistent with animal and in vitro studies that have shown it to promote prostate cancer growth 11 .
Several complex metabolic processes have been postulated to explain this association 47 .
We observed no associations with dietary intake or %PPL for other n-6 PUFAs, generally consistent with other reports for arachidonic acid 3, 22, 27, 32-34, 36, 44, 45 and DGLA 32, 36 .
Several reasons have been proposed for the discrepancies between results from epidemiological and experimental studies in relation to long chain n-3 PUFAs 12 , including: intake of these PUFAs or within-population variability might be too low in some populations to show a protective effect; and n-3 PUFAs are usually analysed without taking into account n-6 PUFAs. The n-3 PUFAs compete with n-6 PUFAs for metabolism into eicosanoids, with those derived from n-6 PUFAs tending to be inflammatory and possibly promoting carcinogenesis 21 . We examined the association of n-6:n-3 PUFA but did not find an association for dietary intake or %PPL. The level of exposure to fatty acids in animal studies tends to be much higher compared with humans and long chain n-3 PUFAs can be biosynthesized from αlinolenic acid more actively in animals than humans 3, 12 , similarly with the biosynthesis of arachidonic acid (a precursor of eicosanoids) from linoleic acid 3 .
We did not observe any association between either %PPL or dietary intake of trans fatty acids, which is consistent with two studies of dietary intakes 22, 27 but inconsistent with positive associations reported by others 38, 48, 49 and the inverse association for serum trans fatty acid 18:1 and 18:2 and high-grade prostate cancer reported by the Prostate Cancer Prevention Trial 44 . These mainly North American populations 38, 44, 48, 49 are likely to have higher average trans fatty intakes and plasma levels than Australia 50 ; this might partly explain why we did not observe any associations with trans fatty acids.
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While some studies have shown different associations by grade or aggressiveness of tumour 24, 34, 44, 45 , suggesting that some fatty acids might differentially affect initiation and progression, few of these formally tested for heterogeneity.
None of our observed associations differed significantly by tumour aggressiveness.
Our findings suggest risk of prostate cancer is positively associated with %PPL SFA, primarily with palmitic acid and weak inversely associated with %PPL MUFA, primarily with oleic acid. Higher risks were also observed for dietary n-6 PUFA, primarily with linoleic acid. However, given the weakness of these associations and the inconsistent results between studies, there is little evidence that dietary fatty acid composition is an important contributor to prostate cancer risk.
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